Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of faricimab in neovascular age-related macular degeneration
jRCT2031210211Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of faricimab in exudative macular degeneration, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Incidence and severity of ocular adverse events and Incidence and severity of non-ocular adverse events. Started Aug 2021; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2031210211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210211.